PD-1

Assets acting on this target.

Class
Anti-PD-1 checkpoint inhibitor
Notes
original target text: PD-1 | original target text: PD-1 (inhibitor)

Programmed cell death protein 1 (PD-1) is a receptor found on the surface of activated T cells, the white blood cells responsible for recognizing and destroying abnormal or infected cells. When PD-1 binds its ligands, PD-L1 or PD-L2, it delivers an inhibitory signal that dampens T-cell activity. This checkpoint exists physiologically to prevent excessive immune responses and autoimmunity, but many tumors exploit it by expressing PD-L1 to suppress the T cells that would otherwise attack them. Blocking PD-1, typically with monoclonal antibodies that occupy the receptor and prevent ligand binding, releases this brake and allows T cells to resume recognizing and killing cancer cells. This approach, known as checkpoint inhibition, has become a foundational strategy across many solid tumors and some hematologic cancers, often used alone or combined with chemotherapy, radiation, or other immune-modulating agents. Because the mechanism restores a natural immune function rather than introducing a new one, its effects can be durable in patients who respond, though the same removal of an inhibitory checkpoint can also unmask immune activity against normal tissues, producing inflammatory side effects. PD-1 remains one of the most extensively targeted immune checkpoints in oncology, illustrating how modulating regulatory signals in the immune system can be harnessed against disease.

By indication

PD-1 drugs compared

27 drugs, stage by indication
27 drugs acting on PD-1: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
CemiplimabRegeneron Pharmaceuticalsmonoclonal antibodyApprovedApproved in Non-Small Cell Lung Cancer; Phase 3 in Melanoma
DostarlimabGlaxoSmithKlinemonoclonal antibodyApprovedApproved in Endometrial Cancer; Approved in Rectal Cancer; Phase 3 in Non-Small Cell Lung Cancer
NivolumabBristol-Myers Squibb, Ono Pharmaceuticalmonoclonal antibodyApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Colorectal Cancer; Approved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Approved in Head and Neck Squamous Cell Carcinoma; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Renal Cell Carcinoma; Approved in Urothelial Carcinoma
Opdivo QvantigBristol-Myers Squibbmonoclonal antibodyApprovedApproved in Advanced Colorectal Cancer; Approved in Advanced Metastatic Colorectal Cancer; Approved in Colorectal Cancer; Approved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Approved in Head and Neck Squamous Cell Carcinoma; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Renal Cell Carcinoma; Approved in Urothelial Carcinoma
PembrolizumabMerck & Co.monoclonal antibodyApprovedApproved in Biliary Tract Cancer; Approved in Breast Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Endometrial Cancer; Approved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Approved in Head and Neck Squamous Cell Carcinoma; Approved in Hepatocellular Carcinoma; Approved in Large B-Cell Lymphoma; Approved in Melanoma; Approved in Merkel Cell Carcinoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Muscle Invasive Bladder Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Renal Cell Carcinoma; Approved in Solid Tumors; Approved in Urothelial Carcinoma; Phase 3 in HR+/HER2- Metastatic Breast Cancer
Pembrolizumab berahyaluronidase alfaKeytruda QlexMerck & Co.monoclonal antibodyApprovedApproved in Bladder Cancer; Approved in Breast Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Gastric Cancer; Approved in Melanoma; Approved in Non-Small Cell Lung Cancer; Approved in Renal Cell Carcinoma; Approved in Solid Tumors
PenpulimabAkeso, Chia Tai Tianqing Pharmaceutical Groupmonoclonal antibodyApprovedApproved in Nasopharyngeal Carcinoma; Phase 3 in Hepatocellular Carcinoma; Phase 3 in Non-Small Cell Lung Cancer
RetifanlimabIncytemonoclonal antibodyApprovedApproved in Merkel Cell Carcinoma; Approved in Squamous Cell Carcinoma of the Anal Canal; Phase 3 in Non-Small Cell Lung Cancer
TislelizumabBeOne Medicinesmonoclonal antibodyApprovedApproved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Phase 3 in Nasopharyngeal Carcinoma; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Small Cell Lung Cancer
ToripalimabCoherus BioSciences, Inc., Shanghai Junshi Biosciencemonoclonal antibodyApprovedApproved in Nasopharyngeal Carcinoma; Phase 3 in Cholangiocarcinoma; Phase 3 in Non-Small Cell Lung Cancer
Abp 234Amgenmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
BAT3306Bio-Thera Solutionsmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
CamrelizumabElevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticalsmonoclonal antibodyPhase 3Phase 3 in Gastric Cancer; Phase 3 in Hepatocellular Carcinoma; Phase 3 in Nasopharyngeal Carcinoma; Phase 3 in Non-Small Cell Lung Cancer; Phase 2/3 in Cervical Cancer
CetrelimabJohnson & Johnsonmonoclonal antibodyPhase 3Phase 3 in Bladder Cancer; Phase 1/2 in Non-Small Cell Lung Cancer
CT-P51Celltrionmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
EnlonstobartCSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Sumgen Biotech Co., Ltd.monoclonal antibodyPhase 3Phase 3 in Cervical Cancer; Phase 3 in Non-Small Cell Lung Cancer
Iparomlimab (QL1604)Qilu Pharmaceuticalmonoclonal antibodyPhase 3Not recorded
MB12Laboratorio Elea Phoenix S.A., mAbxience Research S.L.monoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
SerplulimabAbbott, Accord Healthcare, Eisai, Intas Pharmaceuticals, Kalbe Genexine Biologics, Lotus Pharmaceutical Co., Ltd., Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Shanghai Henlius Biotechmonoclonal antibodyPhase 3Phase 3 in Gastric Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Small Cell Lung Cancer
SintilimabInnovent Biologicsmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
BudigalimabAbbViemonoclonal antibodyPhase 2/3Phase 2/3 in Non-Small Cell Lung Cancer; Phase 2 in Urothelial Carcinoma
SasanlimabPfizermonoclonal antibodyPhase 2/3Phase 2/3 in Non-Small Cell Lung Cancer
BalstilimabAgenus Inc., Zydus Lifesciencesmonoclonal antibodyPhase 2Phase 2 in Cervical Cancer; Phase 2 in Non-Small Cell Lung Cancer
SHR-3045Jiangsu Hengrui PharmaceuticalsundisclosedPhase 2Phase 2 in Rheumatoid Arthritis
IOV-4001Iovance Biotherapeuticscell therapyPhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
OSE-279OSE Immunotherapeuticsmonoclonal antibodyPhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
Bmab1700Biocon Biologicsmonoclonal antibodyPhase 1Not recorded

← all mechanisms